Try our mobile app

General information

Country: UNITED STATES

Sector: Medical Devices

Abbott Laboratories discovers, develops, manufactures, and sells a broad and diversified line of health care products and services. The Company"s products include pharmaceuticals, nutritional, diagnostics, and vascular products. Abbott markets its products worldwide through affiliates and distributors.
Website: abbott.com


  • Bad financial results growth rate 0.0% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (6.0%)
  • Dividend yield for the last twelve months 2.3%
  • Free cash flow yield -8.4% (LTM)
  • Share price is 24.0% higher than minimum and 27.0% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (23.3x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $46.9 mln (-0.023% of cap.)

Key Financials (Download financials)

Ticker: ABT
Share price, USD:  (+0.3%)102.36
year average price 110.34  


year start price 134.57 2025-09-18

max close price 136.62 2025-09-22

min close price 82.56 2026-05-11

current price 102.36 2026-09-17
Common stocks: 1 746 881 140

Dividend Yield:  2.3%
FCF Yield LTM: -8.4%
EV / LTM EBITDA: 23.3x
EV / EBITDA annualized: 24.6x
Last revenue growth (y/y):  +13.0%
Last growth of EBITDA (y/y):  -13.0%
Historical revenue growth:  +5.1%
Historical growth of EBITDA:  +6.9%
Target EV / EBITDA (hist percentile):
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 178 811
Net Debt ($m): 27 504
EV (Enterprise Value): 206 315
EBITDA LTM ($m): 8 870
EV / LTM EBITDA: 23.3x
Price to Book: 3.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-02-04reuters.com

Abbott recalls glucose sensors after seven deaths linked to faulty readings

2026-02-04247wallst.com

5 Goldman Sachs Top Stock Picks Have Huge Upside Potential and Pay Dividends

2026-02-02seekingalpha.com

Abbott: Long-Term Investment Opportunity For Dividend Growth Investors

2026-01-31fool.com

Looking for Passive Income in 2026? 3 Dividend Kings to Buy Hand Over Fist

2026-01-25seekingalpha.com

Abbott Laboratories: Double-Digit Earnings Growth Makes It A Buy

2026-01-24marketbeat.com

Is Abbott's January Pullback a Good Time to Buy?

2026-01-24seekingalpha.com

Abbott Laboratories: The Market's Overreaction Is The Long-Term Investor's Opportunity

2026-01-23zacks.com

Abbott (ABT) is a Top-Ranked Value Stock: Should You Buy?

2026-01-23forbes.com

Is The Fall In Abbott Stock Justified?

2026-01-23seekingalpha.com

Abbott Laboratories: Buy This Dividend King On Sale Now
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data